Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics ...

An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and ...

What is Soleno's lead candidate for rare diseases? Soleno's lead candidate is DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome. Disclaimer: This is an ...